GLPwatch
Pancreatitis
10,395 FAERS reports across 13 drugs
Last updated 2026-07-12 06:04 UTCPancreatitis is a condition where the pancreas, an organ that helps with digestion and blood sugar control, becomes inflamed and can cause pain and digestive problems.
Plain-language definition of the term.
FDA labels for GLP-1 drugs including Byetta, Mounjaro, Ozempic, Rybelsus, Saxenda, Soliqua, Trulicity, Victoza, Wegovy, Xultophy, and Zepbound list pancreatitis as an adverse reaction or warning, while a meta-analysis reports cases of acute pancreatitis associated with different semaglutide regimens.
AI summary of the sources below.
FAERS report counts (as of 2026Q2) reflect voluntary adverse-event reports and cannot establish causation or true frequency; higher counts often track prescription volume. openFDA FAERS ↗
Reports by drug
| Drug | FAERS reports | Quarter |
|---|---|---|
| Victoza | 2,853 | 2026Q2 |
| Byetta | 2,747 | 2026Q2 |
| Trulicity | 1,477 | 2026Q2 |
| Ozempic | 1,041 | 2026Q2 |
| Mounjaro | 926 | 2026Q2 |
| Bydureon | 457 | 2026Q2 |
| Saxenda | 281 | 2026Q2 |
| Zepbound | 218 | 2026Q2 |
| Wegovy | 172 | 2026Q2 |
| Rybelsus | 169 | 2026Q2 |
| Xultophy | 27 | 2026Q2 |
| Soliqua | 26 | 2026Q2 |
| Adlyxin | 1 | 2026Q2 |
Mentioned in FDA labels
Research mentioning pancreatitis (25)
- Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
- Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
- Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.
- Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.
- Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
- A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.
- Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.
- A cohort study of acute pancreatitis in relation to exenatide use.
- Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.
- Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents.
- The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis.
- Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population.
- A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs.
- Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study.
- Association of pancreatitis with glucagon-like peptide-1 agonist use.
- Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial.
- Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.
- Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program.
- Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials.
- Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.